维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

18篇 您的检索式：作者名="Lukyanova"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Vascular endothelial growth factor exression in uterine cervical cancer:correlation with clinicopathologic characteristics and survival显示文摘	Goncharuk IV Vorobjova LI Lukyanova NY		0，，03：	1
	2	Energeticneutralat-omimagingatMercury显示文摘	LukyanovA BarabashS HolmstromM	2004	AdvancesinSpaceResearch2004，33，11：	1
	3	Postoperative autovae- cinotherapy for patients with gastric cancer and expression of some proteins in tumor tissue显示文摘	Bazas VM Lukyanova NY Lisovenko GS	2009	Exp Onco12009，31，3：	1
	4	Vascular endothelial growth factor exression in uterine cervical cancer:correlation with clinicopathologic characteristics and survival显示文摘	Goncharuk IV Vorobjova LI Lukyanova NY	2009	Exp Oncol2009，31，3：	1
	5	Micelles from polyethylene glycol/ phosphatidylethanolamine conjugates for tumor drug delivery显示文摘	LUKYANOVA N GAO Z G TOCHILIN V P		0，，1：	1
	6	Expres sion of drug resistance proteins in triple-receptor-negative lumors as the basis of individualized therapy of the breast cancer patients 显示文摘	Chekhun V F Zhylchuk V E Lukyanova N Y	2009	ExpOncol2009，31，12：	1
	7	Cadmium bioaccumulation in organs of scallop Mizuhopecten yessoensis显示文摘	Evtushenko Z S Lukyanova O N Belcheva N N	1990	Mar Biol1990，104，2：	1
	8	Anthropometric,environmental,and dietary predictors of elevated blood cadmium levels in ukrainian children:Ukraine elspac group显示文摘	Friedman LS Lukyanova EM Kundiev YI		0，，01：	1
	9	Vascular endothelial growth factor exression in uterine cervical cancer:corelation with clinicopathologic characteristics and survival显示文摘	Goneharuk IV Vorobjova LI Lukyanova NY	2009	Exp Oncol2009，31，3：	1
	10	Reversion after ageing in an Mg-Y-Gd-Zr alloy显示文摘	LUKYANOVA E A ROKHLIN L L TABACHKOVA Y N DOBATKINA T V NIKITINA N I	2015	J Alloys Compd2015，635，：	1
	11	The standard enthalpy of formation of silver pivalate显示文摘	LUKYANOVA V A PAPINA T S DIDENKO K V	2008	Journal of Thermal Analysis and Calorimetry2008，92，74：	1
	12	Characteristics of homocysteine-induced multidrug resistance of human MCF-7 breast cancer cells and human A2780 ovarian cancer cells 显示文摘	Lukyanova NY	2010	Exp Oncol2010，32，1：	1
	13	Molecular profileand cell cycle in MCF 7 cells resistant to cisplatin and doxorubicin 显示文摘	LUKYANOVA N Y RUSETSKYA N V TREGUBO- VA N A	2009	Exp On- col2009，31，：	1
	14	A new role for PGRP-S(Tag7)in immune defense:lymphocyte migration is induced by a chemoattractant complex of Tag7 with Mts1显示文摘	DUKHANINA E A LUKYANOVA T I ROMANOVA E A	2015	Cell Cycle2015，14，22：	1
	15	Comparative analysis of secretion of S100A4 metastatic marker by immune and tumor cells显示文摘	Dukhanina EA Lukyanova TI Romanova EA	2008	Bull Exp Biol Med2008，145，1：	1
	16	Relation between cell-to-cell adhesion and angiogenesis and clinico-morphological prognostic factors in patients with gastric cancer显示文摘	Myasoedov DV Bazas VM Lukyanova NY	2008	Exp Oncol2008，30，3：	1
	17	Vascular endothelial growth factor exression in uterine cervical cancer:correlation with clinicopathologic characteristics and survival显示文摘	Goncharuk IV Vorobjova LI Lukyanova NY	2009	Exp Oncol2009，31，3：	1
	18	Boceprevir plus peginterferon/ribavirin for treatment ofchronic hepatitis C in Russia显示文摘AIM: to evaluate addition of boceprevir to peginterferon/ribavirin(PR) in Russian patients with chronic hepatitis C virus(HCV).METHODS: treatment-naive(t N) and treatmentexperienced(t E) patients(who had failed prior treatment with PR for ≥ 12 wk) with chronic HCV genotype 1 infection were enrolled in this placebocontrolled, double-blind study. All patients initially received PR for 4 wk. Patients randomized to control treatment then received PR for an additional 44 wk. t N patients randomized to triple therapy received boceprevir(800 mg three times daily) plus PR for 24 wk and then further therapy according to treatment week 8(t W8) HCV RNA levels. t E patients received boceprevir plus PR for 32 wk and then further therapy according to t W8 HCV RNA levels. treatment was discontinued for t N patients with detectable HCV RNA at t W24 and t E patients with detectable HCV RNA at t W12 because of futility. the primary efficacy end point was sustained virologic response(SVR) defined as undetectable HCV RNA 24 wk after completing all study therapy.RESULTS: SVR was 74.8% in the boceprevir plus PR arm compared with 46.2% in the control arm, with a stratification-adjusted treatment difference of 29.2%(95%CI: 16.4-41.5; P < 0.0001). Rates of SVR were higher in the boceprevir arm in both t N and t E patient groups(t N 78.4% vs 56.3%; t E 69.4% vs 30.0%). Within t E patients, the rates of SVR were higher with boceprevir plus PR compared with PR, regardless of treatment failure type(null responder, partial responder, and relapser). Most patients receiving boceprevir plus PR in both t N(86%) and t E(71%) populations were eligible for reduced treatment duration. Anemia was increased in patients receiving boceprevir plus PR vs PR alone(47.2% vs 24.4%); there was a corresponding increase in ribavirin dose reduction and erythropoietin use. Among patients receiving boceprevir plus PR, SVR rates were similar in patients with anemia(< 10 g/d L) and those without anemia(71.2% vs 77.4%).CONCLUSION: Regulatory approval has been obtained for boceprevir plus PR in Russian patients with HCV genotype 1 infection based on the results of this study.	Vasily Isakov Igor Nikitin Vladimir Chulanov Pavel Ogurtsov Ekaterina Lukyanova Jianmin Long JaniceWahl Frans A Helmond the P08160 Trial Investigators	2016	World Journal of Hepatology2016，8，6：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费